272 related articles for article (PubMed ID: 12090474)
1. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
Ciborowski P; Finn OJ
Clin Exp Metastasis; 2002; 19(4):339-45. PubMed ID: 12090474
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
3. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat.
Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J
Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048
[TBL] [Abstract][Full Text] [Related]
4. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion.
Schroeder JA; Adriance MC; Thompson MC; Camenisch TD; Gendler SJ
Oncogene; 2003 Mar; 22(9):1324-32. PubMed ID: 12618757
[TBL] [Abstract][Full Text] [Related]
5. Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen.
Schuman J; Campbell AP; Koganty RR; Longenecker BM
J Pept Res; 2003 Mar; 61(3):91-108. PubMed ID: 12558945
[TBL] [Abstract][Full Text] [Related]
6. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
Nishimori I; Perini F; Mountjoy KP; Sanderson SD; Johnson N; Cerny RL; Gross ML; Fontenot JD; Hollingsworth MA
Cancer Res; 1994 Jul; 54(14):3738-44. PubMed ID: 8033093
[TBL] [Abstract][Full Text] [Related]
7. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
8. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
9. Influence of acceptor substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. Studies with the MUC1 tandem repeat.
Nishimori I; Johnson NR; Sanderson SD; Perini F; Mountjoy K; Cerny RL; Gross ML; Hollingsworth MA
J Biol Chem; 1994 Jun; 269(23):16123-30. PubMed ID: 8206912
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
11. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.
Poland PA; Kinlough CL; Rokaw MD; Magarian-Blander J; Finn OJ; Hughey RP
Glycoconj J; 1997 Jan; 14(1):89-96. PubMed ID: 9076518
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
Soares M; Hanisch FG; Finn OJ; Ciborowski P
Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
[TBL] [Abstract][Full Text] [Related]
13. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
[TBL] [Abstract][Full Text] [Related]
14. MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation.
Hanisch FG; Stadie TR; Deutzmann F; Peter-Katalinic J
Eur J Biochem; 1996 Feb; 236(1):318-27. PubMed ID: 8617281
[TBL] [Abstract][Full Text] [Related]
15. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.
Kohlgraf KG; Gawron AJ; Higashi M; Meza JL; Burdick MD; Kitajima S; Kelly DL; Caffrey TC; Hollingsworth MA
Cancer Res; 2003 Aug; 63(16):5011-20. PubMed ID: 12941828
[TBL] [Abstract][Full Text] [Related]
16. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue.
Zrihan-Licht S; Vos HL; Baruch A; Elroy-Stein O; Sagiv D; Keydar I; Hilkens J; Wreschner DH
Eur J Biochem; 1994 Sep; 224(2):787-95. PubMed ID: 7925397
[TBL] [Abstract][Full Text] [Related]
17. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.
Müller S; Hanisch FG
J Biol Chem; 2002 Jul; 277(29):26103-12. PubMed ID: 12000758
[TBL] [Abstract][Full Text] [Related]
18. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
[TBL] [Abstract][Full Text] [Related]
19. Identification and functional characterization of a human GalNAc [alpha]2,6-sialyltransferase with altered expression in breast cancer.
Sotiropoulou G; Kono M; Anisowicz A; Stenman G; Tsuji S; Sager R
Mol Med; 2002 Jan; 8(1):42-55. PubMed ID: 11984005
[TBL] [Abstract][Full Text] [Related]
20. Core-glycosylated mucin-like repeats from MUC1 are an apical targeting signal.
Kinlough CL; Poland PA; Gendler SJ; Mattila PE; Mo D; Weisz OA; Hughey RP
J Biol Chem; 2011 Nov; 286(45):39072-81. PubMed ID: 21937430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]